DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

QBW251

Phase Two

Phase Two

Therapeutic Approach

Restore CFTR Function

QBW251 is a type of CFTR Modulator called a “potentiator”. Similar to the drug ivacaftor, this drug would help to facilitate the opening of the chloride channel on the cell surface. This compound is administered through an oral pill.

Status

Phase 2a trials were completed in individuals with residual function mutations.

Sponsor

This program is sponsored by Novartis and is being conducted within CFFT's Therapeutics Development Network.

Contact us about QBW251 >